CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B 细胞淋巴瘤患者嵌合抗原受体工程化 T 细胞治疗中的 FDG-PET/CT 显像：当前证据
英文原题：FDG-PET/CT Imaging in Chimeric Antigen Receptor-Engineered T-Cell Treatment in Patients with B-Cell Lymphoma: Current Evidence.
查看英文原题
FDG-PET/CT Imaging in Chimeric Antigen Receptor-Engineered T-Cell Treatment in Patients with B-Cell Lymphoma: Current Evidence.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
美国食品药品监督管理局和欧洲药品管理局近期批准CAR-T 治疗多种复发/难治性B细胞淋巴瘤。本综述旨在阐明氟脱氧葡萄糖PET/CT影像在改善CAR-T 患者管理中的关键作用，并总结其诊断、预后、疗效预测及治疗指导价值。
展开英文摘要原文
The Food and Drug Administration and the European Medicines Agency have recently approved chimeric antigen receptor-engineered (CAR) T cells to treat several refractory/relapsed B-cell lymphomas. This comprehensive review aims to demonstrate the pivotal role that [ 18 F]-FDG PET/computed tomographic (CT) imaging can play to enhance the care of patients treated with CAR T-cell therapy. To this end, this review deciphers evidence showing the diagnostic, prognostic, predictive, and theragnostic value of [ 18 F]-FDG PET/CT-derived parameters.
论文信息
- 作者
- Abenavoli EM、Linguanti F、Dercle L、Berti V、Lopci E
- 第一作者单位
- Nuclear Medicine Unit, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.Italy
- 通讯作者单位
- Nuclear Medicine Unit, IRCCS-Humanitas Research Hospital, Via Manzoni 56, Rozzano, Milano CAP 20089, Italy. Electronic address: egesta.lopci@cancercenter.humanitas.it.Italy
- 文献类型
- 综述
- 期刊
- PET clinics2024 Oct
- 原文标识
- PubMed 38969565 · DOI 10.1016/j.cpet.2024.05.006